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Background: Increasing numbers of type 2 diabetic and obese patients with enhanced rates of cardiovascular
complications require surgical interventions, however they have a higher incidence of perioperative haemodynamic
complications, which has been linked to adrenergic dysfunction. Therefore, we aimed to determine how α- and
β-adrenoceptor (AR)-mediated haemodynamic responses are affected by isoflurane anaesthesia in experimental
type 2 diabetes and obesity in vivo.
Methods: Sixteen-week old male Zucker type 2 Diabetic Fatty (ZDF) rats, Zucker Obese rats and their lean
counterparts (n = 7-9 per group) were instrumented with radio telemeters to record blood pressure and heart
rate and with vascular access ports for non-invasive intravenous drug delivery in vivo. Haemodynamic effects
of α-AR (phenylephrine; 1-100 μg.kg−1) or β-AR (dobutamine; 2-120 μg.kg−1) stimulation were assessed under
conscious and anaesthetised (isoflurane; 2%) conditions.
Results: Vascular α-AR sensitivity was increased in both diabetic (non-diabetic 80 ± 3 vs. diabetic 95 ± 4 ΔmmHg at
100 μg.kg−1; p < 0.05) and obese (lean 65 ± 6 vs. obese 84 ± 6 ΔmmHg at 20 μg.kg−1; p < 0.05) conscious rats.
Interestingly, anaesthesia exacerbated and prolonged the increased α-AR function in both diabetic and obese
animals (non-diabetic 51 ± 1 vs. diabetic 68 ± 4 ΔmmHg, lean 61 ± 5 vs. obese 84 ± 2 ΔmmHg at 20 μg.kg−1;
p < 0.05). Meanwhile, β-AR chronotropic sensitivity was reduced in conscious diabetic and obese rats (non-diabetic
58 ± 7 vs. diabetic 27 ± 8 Δbpm, lean 103 ± 12 vs. obese 61 ± 9 Δbpm at 15 μg.kg−1; p < 0.05). Anaesthesia normalised
chronotropic β-AR responses, via either a limited reduction in obese (lean 51 ± 3 vs. obese 66 ± 5 Δbpm; NS at
15 μg.kg−1) or increased responses in diabetic animals (non-diabetic 49 ± 8 vs. diabetic 63 ± 8 Δbpm, at 15 μg.kg−1;
NS at 15 μg.kg−1).
Conclusions: Long term metabolic stress, such as during type 2 diabetes and obesity, alters α- and β-AR function, its
dynamics and the interaction with isoflurane anaesthesia. During anaesthesia, enhanced α-AR sensitivity and
normalised β-AR function may impair cardiovascular function in experimental type 2 diabetes and obesity.
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The rapid expansion of the type 2 diabetes and obesity
co-epidemics impacts heavily on cardiovascular health.
One clinically important, but often overlooked, cardio-
vascular consequence is that diabetic and obese patients
have increased requirements for surgical treatments. Fol-
lowing surgery they have longer hospital stays and poorer
survival compared to non-diabetic and lean patients [1-3].
Importantly, patients with metabolic syndrome are sub-
ject to a higher incidence of perioperative haemodynamic
complications, even for non-cardiac related surgeries, which
most likely relates to changes in autonomic control of the
cardiovascular system [2,4-6].
Long-term changes in metabolism, such as during the
metabolic syndrome [7], are characterised by increased
muscle sympathetic nerve activity [8,9] and increases
in plasma (nor)epinephrine levels [10], suggesting over-
all central sympathetic over-activation [7]. Consequently,
several ex vivo studies demonstrated decreased β-AR
expression in [11-14] and reduced β-AR responsive-
ness of [14-17] the heart in diabetes, with similar reports
in obesity [18-20]. Less attention has focused on α-ARs,
with ex vivo studies or studies in anaesthetised rats
variably reporting unchanged [16,21], impaired [22,23]
or enhanced [24,25] α-AR activity in the metabolic
syndrome.
While the long-term metabolic stress of diabetes and
obesity leads to haemodynamic dysregulation [4,26], car-
diovascular function is also acutely challenged in the
perioperative setting [4,27]. Diabetes and obesity are
both known to augment cardiovascular responses to an-
aesthetics [16,28,29]; and the well described cardiopro-
tective effects of volatile anaesthetics are reduced under
conditions of metabolic stress [30]. For instance, sevoflur-
ane elicited greater impairments in myocardial blood
flow in a pilot study of type 2 diabetic patients [31]. Iso-
flurane anaesthesia also impairs baroreflex responsiveness
[32], and obesity is associated with impaired baroreflex
sympatho-inhibition [33]; both effects which are thought
to be mediated via augmentation of central nervous sys-
tem pathways. Furthermore, Amour et al. [16] showed in
isolated papillary muscles that type 1 diabetes attenuated
the potentiation of α- and β-AR responses by halogenated
anaesthetics, suggesting an interaction between anaes-
thetic and metabolic-mediated α- and β-AR dysfunction.
However, this approach does not address the peripheral
and neural effects present in vivo, nor examine changes
in type 2 diabetes. Furthermore, the lack of in vivo data
under conscious conditions, limits the interpretation of
anaesthetic effects on α- and β-AR function.
Therefore, the present study aimed to assess how isoflur-
ane anaesthesia affects the α- and β-AR-mediated haemo-
dynamic responses in type 2 diabetes in vivo. To assess the
direct effects of anaesthesia we measured haemodynamicresponses in free-moving conscious and in isoflurane
anaesthetised type 2 diabetic (Zucker Diabetic Fatty
(ZDF)) rats following α- and β-AR stimulation. To this
end, rats were implanted with a radio telemetric transmit-
ter and a vascular access port to measure in vivo abdom-
inal aortic blood pressure and inject intravenous drugs,
respectively [34]. These measures were repeated in obese
(Zucker) rats to determine whether the observed changes
were a specific effect of type 2 diabetes, or a more general
feature of metabolic syndrome.
Materials and methods
Animals
All procedures were approved by the University of Otago
Animal Ethics Committee and were conducted in accord-
ance with the New Zealand Animal Welfare Act (1999).
Zucker Diabetic Fatty (ZDF) rats are derived from a se-
lected subset of the Zucker strain, which spontaneously
develop diabetes from 12 weeks of age due to impaired
pancreatic beta-cell function [35]. Zucker Obese rats have
a homozygous missense mutation in the leptin receptor
gene (fa/fa) leading to impaired satiety signalling and hy-
perphagia [36,37]. These strains are well-accepted models
of type 2 diabetes mellitus and obesity, respectively, and
were compared to their own lean littermates as in-strain
controls.
Male rats (N= 39; Charles River Laboratories, Wilmington,
MA, USA) were housed at 20 ± 1°C under a 12 hour
light–dark cycle and provided with food and water ad libi-
tum. All ZDF animals were maintained on Purina 5008
diet (LabDiet®, St Louis, MO, USA) as recommended by
the supplier, while Zucker rats were fed chow (Rat and
Mouse cubes; Specialty Feeds, WA, Australia). Animals
were gentled daily for one week prior to surgery (Figure 1a).
Plasma samples were collected via the tail vein following
an 8-hour fast 4 days prior to surgery. Plasma glucose con-
centrations were determined using a glucometer (Roche,
Basel, Switzerland) and insulin was measured by ELISA
(Millipore, Billerica, MA, USA).
Surgical procedures
Dual implantation of a radio telemeter and vascular ac-
cess port was performed on 16-week old animals under
2–2.5% isoflurane anaesthesia (Minrad Inc, Bethlehem,
PA, USA) as previously described [34] with strict adherence
to aseptic procedures. Analgesia (5 mg.kg−1 carprofen; Nor-
brook, Newry, Northern Ireland) and antibiotic (30 mg.kg−1
trimethoprim and sulphamethazine; Virbac, Carros, France)
were administered subcutaneously.
Vascular Access Ports (VAP™; ROP-3H, hydromer-coated
polyurethane, 3Fr; Access Technologies, Skokie, IL, USA)
were primed with heparin sodium (100 IU.mL−1; Hospira
Australia, Mulgrave, Australia). The VAP reservoir was se-
cured on the back of the animal between the scapulae,
Figure 1 Experimental protocols. Overview of the study, indicating one week gentling and post-surgical recovery periods, and twice-weekly
experimental sessions for randomised protocols (a). Protocols for the acute administration of incrementing doses of the α-adrenergic agonist
phenylephrine at five minute intervals (b), and the β-adrenergic agonist dobutamine at ten minute intervals (c). Sodium nitroprusside (SNP) was
injected at the initiation of each experiment to confirm vascular access port (VAP) patency. Sal represents saline injection to flush the VAP. All
solutions were administered as a bolus.
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femoral vein. A radio telemeter with pressure sensitive
tip (TRM53P; Telemetry Research, Millar Instruments,
Houston, TX, USA) was implanted into the abdominal
aorta. Animals were allowed one-week post-surgical recovery
before experimentation commenced (Figure 1a). The VAP
was flushed with 0.4 mL heparin sodium (100 IU.mL−1) at
minimum twice-weekly to maintain patency.
Experimental procedures
Experiments were performed in random order twice-
weekly to reduce stress to the animals, as well as ensur-
ing complete drug clearance and avoiding potential
desensitisation of adrenoceptors. This 3–4 day allowance
between randomised experimental sessions, along with
the 7 day post-surgical recovery period, also served to
minimise potential effects of repeated exposure to
volatile anaesthetics, generally described as lasting 24–72
hours [38]. VAPs were accessed under strict aseptic condi-
tions using a Huber point needle (PG24-625; Access
Technologies, Skokie, IL, USA), following application
of a short-acting local analgesic (5% lignocaine/prilocaine;
AstraZeneca, North Ryde, NSW, Australia).Haemodynamic measures were equilibrated for 15 mi-
nutes following restraint and needle insertion. The nitric
oxide donor sodium nitroprusside (SNP; 6.25 μg.kg−1) was
administered at the beginning of each experimental ses-
sion, as used previously to confirm VAP patency over the
course of the study [34]. Isoflurane is a volatile anaesthetic
commonly used in the clinical setting, due to its min-
imal haemodynamic effects and rapid recovery times.
For measures under anaesthetised conditions, induction
was undertaken at 5% isoflurane with maintenance at 2%
isoflurane. Incrementing doses of the α-adrenergic agonist
phenylephrine (1-100 μg.kg−1) and β-adrenergic agonist
dobutamine (2-120 μg.kg−1) were administered at five or
ten minute intervals, respectively (Figure 1b and c). Any
access via the VAP was concluded by injection of 0.4 mL
Heparin sodium (100 IU.mL−1) to prevent coagulation. All
chemicals were from Sigma-Aldrich (St Louis, MO, USA)
and diluted in saline (0.9% NaCl; Baxter, Toongabbie,
Australia) unless otherwise stated.
Data and statistical analysis
Blood pressure data was derived from the telemeter ac-
cording to the manufacturer’s instructions, and acquired
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New Zealand). Heart rate (HR) and mean arterial pres-
sure (MAP) were derived from blood pressure record-
ings using the LabChart® blood pressure module, and
averaged over every ten consecutive cycles. Basal haemo-
dynamic data for an individual animal were averaged
over up to four conscious replicates and up to two repli-
cate anaesthetised measures. Haemodynamic responses
were assessed as the calculated change between the peak
response to and the baseline immediately preceding
each individual bolus injection. Time course dynamics
were assessed over 5 second averages. Statistical ana-
lysis was performed for baseline characteristics via t-test,
or Mann–Whitney rank sums test where the assumptions
were not met; or via two-way repeated measures ANOVA
for all haemodynamic data. Differences between groups
were identified using Student-Newman-Keuls post-hoc
analysis (Sigmaplot™ 12.0, Systat Software Inc, Chicago,
IL, USA) and significance assumed at the level of p < 0.05.
Data are expressed as mean ± standard error of the
mean (SE).
Results
Baseline characteristics and haemodynamics of type 2
diabetic rats
Type 2 diabetic rats exhibited body weights 25% higher
than their non-diabetic littermates (Table 1). This was
accompanied by significantly greater abdominal adipos-
ity, as indicated by epididymal fat pad weight. Type 2
diabetic animals also exhibited both hyperglycaemia and
hyperinsulinemia, characteristic of the condition.
Baseline haemodynamics were assessed under con-
scious resting conditions or following stabilisation of 2%Table 1 Baseline characteristics and haemodynamics
Non-Diabetic
Body weight (g) 333 ± 6
Epididymal fat weight (g) 1.45 ± 0.16
Epididymal fat/Tibia length (g.cm−1) 0.40 ± 0.06
Heart weight (g) 1.49 ± 0.06
Heart weight/Tibia length (g.cm−1) 0.41 ± 0.02
Fasting plasma glucose (mmol.L−1) 6.4 ± 0.4
Fasting plasma insulin (ng.mL−1) 1.2 ± 0.3
Mean arterial pressure (mmHg)
Conscious 110.2 ± 4.7
Anaesthetised 87.5 ± 4.4†
Heart rate (bpm)
Conscious 366 ± 16
Anaesthetised 314 ± 10†
Baseline characteristics of 16 week old Zucker Diabetic Fatty (ZDF) and Zucker Obe
littermates, †significantly different anaesthetised vs. conscious, n = 6-9, p < 0.05, valuisoflurane anaesthesia (Table 1). Type 2 diabetic animals
were normotensive with a markedly reduced HR under
conscious conditions; in agreement with multiple litera-
ture reports [10,39]. Isoflurane anaesthesia significantly
reduced both HR and MAP in all animals, eliminating
differences in HR.
α-adrenergic sensitivity is increased in conscious and
anaesthetised type 2 diabetic rats
Administration of phenylephrine (PE), an α-AR agonist,
primarily elicited a rapid, transient increase in MAP in a
dose-dependent manner (Figure 2). Conscious type 2
diabetic animals demonstrated a greater increase in
MAP with the highest dose of phenylephrine (Figure 2a). It
is unclear whether this represents maximal PE-mediated
vasoconstriction, as the extreme bradycardia (Figure 2c)
prevented testing of higher doses. However, higher doses
of PE are unlikely to be used clinically, with a therapeutic
dose range for PE of approximately 0.5-9ug.kg−1.min−1
[40]. Under anaesthesia the maximal MAP response to
α-AR stimulation was not changed, however the increase
in MAP at lower, therapeutic doses of PE was significantly
reduced in both groups (Figure 2b). This isoflurane-
induced decrease in pressure was less in the type 2 dia-
betic rats, accentuating the differential α-AR sensitivity in
diabetes in vivo.
Secondary to the changes in MAP, PE elicited a dose-
dependent reduction in HR (Figure 2c and d). Conscious
diabetic animals experienced a reduced bradycardic re-
sponse to high-dose PE (Figure 2c). Given the greater max-
imum recorded peak MAP (Figure 2a), this indicates a
limited baroreflex capacity in conscious type 2 diabetic rats
(diabetic −2.1 ± 0.2 bpm.mmHg−1 vs. non-diabetic −3.0 ±Diabetic Lean Obese
417 ± 14* 364 ± 7 584 ± 16*
6.38 ± 0.67* 2.77 ± 0.29 17.57 ± 1.04*
1.92 ± 0.18* 0.65 ± 0.07 4.57 ± 0.31*
1.52 ± 0.06 1.37 ± 0.06 1.56 ± 0.08
0.44 ± 0.02 0.32 ± 0.02 0.40 ± 0.02*
19.5 ± 4.4* 6.6 ± 0.3 7.1 ± 0.8
8.0 ± 2.2* 1.1 ± 0.4 12.8 ± 3.2*
114.4 ± 3.5 106.2 ± 4.7 125.9 ± 5.5*
90.8 ± 7.6† 86.1 ± 5.8† 111.2 ± 5.0*†
317 ± 11* 389 ± 10 391 ± 10
292 ± 4† 365 ± 7† 365 ± 6†
se rats and their lean littermates. *significantly different from control
es are means ± SE.
Figure 2 α-adrenoceptor agonist responses in Zucker Diabetic Fatty rats. Peak change in mean arterial pressure (top) and heart rate (bottom)
in response to 1–100 μg.kg−1 phenylephrine under conscious conditions (a and c) and during isoflurane anaesthesia (b and d). *significantly different
from non-diabetic littermate controls, †significantly different from conscious measure and # significant overall group difference, n = 8, p < 0.05, values
are means ± SE.
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markedly reduced the baroreflex-mediated bradycardia in
all animals, eliminating the between group differences.
β-adrenergic sensitivity is reduced in conscious type 2
diabetic rats
Administration of dobutamine, a non-specific β-AR agon-
ist, primarily elicited a dose-dependent increase in HR in
both non-diabetic and type 2 diabetic animals under all
conditions (Figure 3). Conscious diabetic rats were less
sensitive to dobutamine than their non-diabetic counter-
parts (Figure 3a), as evidenced by a significantly reduced
response to the mid-dose of dobutamine (15 μg.kg−1).
This dose is within the therapeutic range of approximately
2-20 ug.kg−1.min−1 [40], making the observed chronotro-
pic difference particularly relevant for the clinical setting.
In addition, similar percentage increases in heart rate have
been described following injection of 3.2 and 12.2 μg.kg−1
dobutamine in healthy human volunteers [41]; indicat-
ing that effective doses are equivalent between the species.
Isoflurane anaesthesia reduced the maximal β-AR-
mediated chronotropic response in non-diabetic animals
(Figure 3b). Conversely, in type 2 diabetic animals an-
aesthesia increased β-AR sensitivity in the mid-range
(Figure 3b) compared to the conscious condition, withno change at the maximal dose. Thus, isoflurane normal-
ised β-AR responsiveness in type 2 diabetic rats in vivo.
Dobutamine administration also caused a transient de-
crease in MAP under all conditions, most likely attribut-
able to vasodilation via stimulation of β2-ARs in the
vasculature (Figure 3c and d). No significant differences
in β-AR-mediated vasodilation were observed between
non-diabetic and type 2 diabetic animals.
Baseline characteristics and haemodynamics of obese rats
Following the findings of altered adrenoceptor function
and responses to anaesthesia in type 2 diabetic animals
in vivo, we aimed to determine whether these disturbances
were specifically attributable to hyperglycaemia or a gen-
eral feature of obesity and the metabolic syndrome.
Zucker obese rats exhibited markedly higher body
weights than their lean littermates, with an average 60%
increase, accompanied by a large increase in epididymal
fat pad weight (Table 1). Cardiac hypertrophy became
evident in obese animals when heart weight was adjusted
to tibia length as a proxy for body size, despite no sig-
nificant differences in tibia length (data not shown).
Metabolic assessment showed hyperinsulinemia with
normal glucose levels in obese animals, indicating insu-
lin resistance.
Figure 3 β-adrenoceptor agonist responses in Zucker Diabetic Fatty rats. Peak change in heart rate (top) and mean arterial pressure
(bottom) in response to 2-120 μg.kg−1 dobutamine under conscious conditions (a and c) and during isoflurane anaesthesia (b and d).
*significantly different from non-diabetic littermate controls and †significantly different from conscious measure, n = 7-8, p < 0.05, values
are means ± SE.
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played significantly increased MAP under both con-
scious and anaesthetised conditions (Table 1).
α-adrenergic sensitivity is increased in conscious and
anaesthetised obese rats
Conscious obese rats showed a larger increase in MAP with
α-AR stimulation than their lean littermates (Figure 4a),
suggesting increased α-AR sensitivity in obesity in vivo.
Isoflurane anaesthesia reduced the MAP response to low
doses of PE in lean, but not obese, animals (Figure 4b), ex-
acerbating the differential α-AR-mediated vasoconstriction.
Under conscious conditions, obese rats exhibited in-
creased baroreflex-mediated bradycardia in response to
8 μg.kg−1 PE (Figure 4c). However, with a greater corre-
sponding increase in MAP (Figure 4a), this represents
an unchanged baroreflex sensitivity (lean −2.3 ± 0.3 vs.
obese −2.5 ± 0.2 bpm.mmHg−1; NS). Conscious obese
rats also showed a trend toward reduced maximal brady-
cardia (Figure 4c; p = 0.052), similar to that seen in type
2 diabetic animals. Baroreflex-mediated bradycardia
was generally reduced during anaesthesia (Figure 4d), as
seen in the ZDF rats, removing potential obesity-derived
differences.β-adrenergic sensitivity is reduced in conscious obese
rats
Conscious obese rats displayed a reduced β-AR response
following dobutamine administration compared to their
lean counterparts (Figure 5a), an effect most pronounced
at the mid-dose (15 μg.kg−1) similar to type 2 diabetic rats.
Isoflurane anaesthesia significantly reduced the maximal
β-AR-mediated chronotropic response in both groups
(Figure 5b), being particularly effective in lean animals
where the response was reduced across the entire dose
curve. The general reduction in β-AR response during an-
aesthesia eliminated sensitivity differences between the
obese animals and their controls.
Dobutamine-mediated vasodilation was slightly greater
in obese than lean rats, with variable significance across
the dose–response curve (Figure 5c). Under anaesthesia
the differences between lean and obese animals were ab-
sent (Figure 5d).
α-adrenergic responses are prolonged by anaesthesia and
type 2 diabetes or obesity
The interesting observation that the differential α-AR re-
sponsiveness in type 2 diabetes and obesity in vivo was
exacerbated by anaesthesia was further considered with
Figure 4 α-adrenoceptor agonist responses in Zucker Obese rats. Peak change in mean arterial pressure (top) and heart rate (bottom)
in response to 1–100 μg.kg−1 phenylephrine under conscious conditions (a and c) and during isoflurane anaesthesia (b and d). *significantly
different from lean littermate controls, †significantly different from conscious measure and # significant overall group difference, n = 8, p < 0.05, values
are means ± SE.
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tion. With the rapid effects of PE, no change in time to
peak response or time to return to plateau of note was
apparent between any groups or conditions. However,
observation of the full response time courses indicated
significant effects of both anaesthesia and diabetes to
prolong the elevated MAP following α-AR stimulation
(Figure 6a-c). Similar, and more pronounced, prolonga-
tion of the α-AR effects was observed in obese animals
(Figure 6d-f ). A significant interaction between anaes-
thesia and obesity was particularly apparent following
administration of 20 μg.kg−1 PE (Figure 6d). Isoflurane an-
aesthesia did not prolong the MAP response to equivalent
α-AR stimulation in lean animals. Increasing the α-AR
agonist concentration uncovered independent, but addi-
tive, effects of obesity and anaesthesia to exacerbate α-AR-
mediated vasoconstriction (Figure 6e and f ). Notably,
anaesthesia appeared to primarily exacerbate the MAP
response at the early to mid-time points, while obes-
ity prolonged MAP elevation in the later stages of the
response.
The time taken to reach peak β-AR HR response was
similar in all conscious animals (non-diabetic 31 ± 8 vs.
diabetic 48 ± 9 s, lean 34 ± 4 vs. obese 38 ± 5 s at 120 μg.
kg−1; NS). However, during anaesthesia the time to peak
response was significantly prolonged in control animalscompared to their diseased littermates (non-diabetic 68 ±
6 vs. diabetic 47 ± 3 s, lean 66 ± 5 vs. obese 39 ± 4 s
at 120 μg.kg−1; p < 0.05), despite similar peak values
(Figures 3b and 5b). Moreover, the time required for
HR to return to plateau from peak dobutamine response
was slightly faster in conscious type 2 diabetic animals at
the maximal dose (non-diabetic 177 ± 41 vs. diabetic 94 ±
19 s; p < 0.05). Isoflurane non-selectively slowed this HR
recovery time to plateau. Therefore, alterations in the
dynamics of β-AR function in type 2 diabetes and obesity,
particularly during anaesthesia, may be reflected more by
a briefer, rather than smaller, response.
Anaesthesia differentially affects adrenergic responses in
non-diabetic and type 2 diabetic rats
The broad findings of this study can be summarised in
the peak responses to mid-doses of PE (20 μg.kg−1) and
dobutamine (15 μg.kg−1). Conscious type 2 diabetic and
obese rats exhibited significantly increased α-adrenergic
and reduced β-adrenergic sensitivity. Isoflurane anaesthe-
sia decreased α-adrenergic responsiveness in non-diabetic
but not in type 2 diabetic animals, while it increased
β-adrenergic responses in type 2 diabetic rats with no
effect on control responses (Figure 7). Anaesthetised
obese rats similarly exhibited maintenance of the increased
α-AR sensitivity, and normalisation of the β-adrenergic
Figure 5 β-adrenoceptor agonist responses in Zucker Obese rats. Peak change in heart rate (top) and mean arterial pressure (bottom) in
response to 2-120 μg.kg−1 dobutamine under conscious conditions (a and c) and during isoflurane anaesthesia (b and d). *significantly different
from lean littermate controls, †significantly different from conscious measure and # significant overall group difference, n = 7-9, p < 0.05, values
are means ± SE.
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(data not shown). Thus, anaesthetised type 2 diabetic and
obese animals experience a significantly accentuated ad-
renergic load.
Discussion
This is the first study to determine the interaction between
α- and β-adrenergic function and isoflurane anaesthesia
in vivo under physiological conscious and anaesthetised
conditions. This conscious-anaesthesia approach reveals
augmented vascular α-AR sensitivity and reduced cardiac
chronotropic β-AR sensitivity in conscious free-moving
type 2 diabetic and obese animals. Moreover, isoflurane
anaesthesia exacerbated the increased vascular α-AR sen-
sitivity in both disease models, while normalising the
chronotropic β-AR responses in obese rats and surpris-
ingly increasing the chronotropic β-AR sensitivity in type
2 diabetic rats. These results show that chronic metabolic
stress, such as during type 2 diabetes and obesity, alters
α- and β-adrenoceptor function in vivo, its dynamics
and the interaction with anaesthesia; reducing the haemo-
dynamic capacity of the cardiovascular system to com-
pensate during times of acute stress. Furthermore, the
differential α- and β-adrenergic responses described in
type 2 diabetes and obesity during isoflurane anaesthesiaemphasise the importance of examining pharmacological
effects under physiological conditions.
Several studies have found increased α-AR vascular re-
activity in isolated and anaesthetised preparations from
both type 1 and type 2 diabetic (20, 30, 38) and obese
models (28, 29, 37). Alternatively, some studies reported
unchanged [18,21] or reduced [43,44] vascular α-AR re-
sponses. However use of low phenylephrine doses that
also failed to discern a difference in our study [18] or non-
specific α-AR stimulation with noradrenaline [43,44], may
explain these differences. The present study shows aug-
mented vascular α-AR responsiveness, in magnitude and
in duration, in conscious type 2 diabetic and obese ani-
mals, at clinical doses of phenylephrine (32).
The reduced cardiac β-AR sensitivity observed aligns
with and extends literature reports. During the metabol-
ically compromised state of diabetes, it is suggested that
the sympathetic drive to the heart is increased [4,7],
eventually desensitising the adrenergic control of the heart
and reducing its function [45]. Reduced β-AR activity has
been described in both isolated heart [14-16,46] and in
anaesthetised in vivo preparations [12] of streptozotocin-
induced type 1 diabetes. Furthermore, we have recently
described the loss of β-AR responsiveness with type 2
diabetes in human right atrial cardiac muscles [17].
Figure 6 Time courses of α-adrenoceptor stimulation. Change in mean arterial pressure in response to 20 (a and d), 40 (b and e) and 100
(c and f) μg.kg−1 phenylephrine in Zucker Diabetic Fatty (a, b and c) and Zucker Obese (d, e and f) rats. Statistical significance is indicated by
the bars above each graph; con: conscious, ana: anaesthetised, ND: non-diabetic, D: diabetic, L: lean, Ob: obese. n = 7-9, p < 0.05, values are
means ± SE.
Figure 7 Summary of α- and β-adrenoceptor function in conscious and anaesthetised Zucker Diabetic Fatty rats. Peak responses to
mid-dose phenylephrine (a) or dobutamine (b). *significantly different from lean littermate controls, †significantly different from conscious
measure, n = 7-9, p < 0.05, values are means ± SE.
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derived from heart tissue from [19,20] and a single
report in conscious [18] obese rodents. However, the
present study provides the first evidence of increased
and prolonged vascular α-AR sensitivity and reduced
chronotropic β-AR sensitivity in well-developed models of
both type 2 diabetes and obesity in vivo under conscious
conditions.
While the mechanisms underlying the altered AR func-
tion are poorly understood, and determination was not
the aim of this study, changes in AR expression have been
implicated. Elevated cardiovascular α1-AR expression has
been described in various models of the metabolic syn-
drome [46-48], although decreased α-AR density has also
been reported [48,49]. This α1-AR variability is proposed
to be attributable to disease duration [24,49], with a bi-
phasic expression pattern providing a compensatory
response to the progressive α-AR sensitisation [48,49].
However, during ganglionic blockade α-AR responsive-
ness was found to be unchanged, indicating that the effect
may originate downstream [21]. Decreased expression
of β1-ARs was shown in myocardium of type 1 dia-
betic rodent models [11,13,50]. However, we found un-
changed β1-AR expression in right atrial tissue from
type 2 diabetic patients [17]. Similarly, Carroll et al.
[42] found unchanged overall β-AR density in obese
rabbit ventricles, and similar to α-ARs, suggested that de-
fective β-AR function in obesity may originate down-
stream of the receptors themselves. Moreover, we have
recently shown that the haemodynamic effects observed
using our technique are not due to the potential con-
founders of volume or injection stress in conscious
animals [34]. Thus, further research, particularly into
expression and function of α-AR in the vasculature and
β-AR in the sinoatrial node, is warranted to explain these
haemodynamic and chronotropic differences.
Much of the previous experimental evidence for
α- and β-AR-dysfunction has been derived from models
of type 1 diabetes, and conducted in anaesthetised or iso-
lated heart or vessel preparations. Therefore, this study,
using improved conscious in vivo techniques, confirms
the relevance of these α- and β-AR-dysfunctions in type 2
diabetes and obesity under physiological conditions and
provides valuable new insights. Additionally, the paucity
of suitable data in conscious animals has made it difficult
to elucidate the effects of anaesthetics per se, and few in-
vestigations have addressed this issue. Amour et al. [16]
showed in an interesting study that halogenated anaes-
thetics, including isoflurane, increased both α-AR and
β-AR inotropic responses in isolated hearts. This is sup-
ported by our observation of enhanced β-AR-generated
HR responses in type 2 diabetic animals, but not by
the absence of isoflurane-potentiated β-AR chronotropic
responses in non-diabetic rats or the reduced α-ARsensitivity. This indicates the importance of in vivo investi-
gations, including neural, hormonal and vascular feed-
backs, which are most likely geared to compensate for
excessive fluctuations in the cardiovascular system.
It is unclear how defects exclusively at the α- and β-
ARs themselves would directly interact with anaesthe-
sia. Likewise, simple interruption of central autonomic
signalling by anaesthetics would be unlikely to select-
ively interact with α-AR function. The phenylephrine-
generated baroreflex-induced changes in HR were overall
markedly depressed under isoflurane. Thus, it could be
speculated that isoflurane prevents appropriate central
control of sympathetic withdrawal during MAP elevation
in the vasculature causing an anaesthetic-mediated ex-
acerbation of α-AR sensitisation in type 2 diabetic and
obese rats.
By utilising models of type 2 diabetes and obesity with a
common underlying defect in leptin signalling, we were
able to directly address the influence of hyperglycaemia.
The observed alterations in α- and β-AR function were
broadly similar between type 2 diabetic and obese rats.
Thus, these impairments are likely to be a function of
the general metabolic syndrome components of over-
weight and insulin resistance, rather than the hyper-
glycaemic phenotype of diabetes; in agreement with
previous findings that α- and β-AR dysfunction is not
tied to the development of type 2 diabetes [51]. Further-
more, as the effects were more severe in morbidly obese
rats, and less pronounced in the overweight type 2 dia-
betic animals, it appears that obesity may be the primary
causal defect.
Regardless of the cause of exacerbated metabolic α-
and β-AR dysfunction, differences in α- and β-AR re-
sponsiveness (in magnitude and duration) remain an
important consideration in this large patient group. Dur-
ing chronic metabolic stress, such as obesity and type 2
diabetes, sympathetic drive to the heart is suggested to be
increased [4,7]; which may be partially offset by the ob-
served reduction in β-AR sensitivity. Enhanced and pro-
longed α-AR responsiveness and the resultant chronic
excess cardiovascular pressure could lead to cardiac com-
plications, including increased afterload, cardiac remodel-
ling and hypertrophy [52]. During anaesthesia, the dual
effects of exacerbating differences in α-AR response and
normalising β-AR function will likely act in concert in
type 2 diabetes and obesity to further increase cardiovas-
cular stress. This indicates that chronic metabolic stress
limits the capacity of the cardiovascular system to respond
when challenged by acute stressors such as anaesthesia. In
particular, the interaction between metabolic syndrome
and anaesthesia to exaggerate phenylephrine-mediated el-
evations in MAP suggests that type 2 diabetic and obese
patients may be exposed to increased pharmacological
stress during surgery.
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In summary, this study is the first to determine the
haemodynamic consequences of altered α- and β-AR
function in conscious type 2 diabetic and obese animals,
and the interaction between adrenergic dysfunction and
isoflurane anaesthesia in vivo. Under conscious physio-
logical conditions, type 2 diabetic and obese rats exhibited
increased α-AR and decreased β-AR responses. Mean-
while, during anaesthesia, enhanced α-AR sensitivity and
normalised β-AR function may further impair cardiovas-
cular function in type 2 diabetes and obesity.
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